Alpha 2.0
Login Register
» Authors » M J Mozziconacci

M J Mozziconacci

Explore the profile of M J Mozziconacci including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 45
Citations 612
Followers 0
Related Specialties
Hematology
Oncology
Molecular Biology
Top 10 Co-Authors
D Sainty
M Lafage-Pochitaloff
N Vey
D Birnbaum
M Chaffanet
C Arnoulet
J Adelaide
V Gelsi-Boyer
A Murati
V Brunel
Published In
Leukemia
Br J Haematol
Cancer Genet Cytogenet
Blood Cancer J
Genes Chromosomes Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, et al.
Eur J Haematol . 2023 Nov; 112(4):530-537. PMID: 38031389
Objectives: To compare the efficacy of venetoclax-azacitidine (VEN-AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML). Methods: We retrospectively analysed R/R...
2.
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
Collignon A, Hospital M, Montersino C, Courtier F, Charbonnier A, Saillard C, et al.
Blood Cancer J . 2020 Jun; 10(6):64. PMID: 32488055
Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to...
3.
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome
Bouchacourt B, Hospital M, Zemmour C, Rey J, DIncan E, Charbonnier A, et al.
Ann Hematol . 2020 Feb; 99(4):773-780. PMID: 32088745
Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective...
4.
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
Collette Y, Prebet T, Goubard A, Adelaide J, Castellano R, Carbuccia N, et al.
Blood Cancer J . 2015 Mar; 5:e292. PMID: 25768406
No abstract available.
5.
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
Cabagnols X, Defour J, Ugo V, Ianotto J, Mossuz P, Mondet J, et al.
Leukemia . 2014 Sep; 29(1):249-52. PMID: 25212275
No abstract available.
6.
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
Brecqueville M, Cervera N, Adelaide J, Rey J, Carbuccia N, Chaffanet M, et al.
Blood Cancer J . 2012 Jul; 1(8):e33. PMID: 22829192
No abstract available.
7.
Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
Brecqueville M, Cervera N, Gelsi-Boyer V, Murati A, Adelaide J, Chaffanet M, et al.
Blood Cancer J . 2012 Jul; 1(5):e18. PMID: 22829153
No abstract available.
8.
Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies
Adelaide J, Gelsi-Boyer V, Rocquain J, Carbuccia N, Birnbaum D, Finetti P, et al.
Leukemia . 2010 Jun; 24(8):1539-41. PMID: 20555362
No abstract available.
9.
NUP98-HMGB3: a novel oncogenic fusion
Petit A, Ragu C, Della-Valle V, Mozziconacci M, Lafage-Pochitaloff M, Soler G, et al.
Leukemia . 2009 Dec; 24(3):654-8. PMID: 19956199
No abstract available.
10.
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J, et al.
Leukemia . 2009 Oct; 24(2):469-73. PMID: 19865112
No abstract available.